

UNIVERSITY OF MIAMI
Curriculum Vitae
Standard Format

1. DATE: May 15, 2018

I. PERSONAL:

2. Name: Michael A. Kolber, Ph.D., M.D.
3. Home Phone: 305-284-1235
4. Office Phone: 305-243-4791
5. Office Address: Clinical Research Building # 859
1120 NW 14th Street
Miami, FL 33136
6. Current Academic Rank: Professor of Medicine
6a. Current Track of Appointment: Tenure-earning track: tenured
7. Primary Department: Medicine, Division of Infectious Diseases
8. Secondary or Joint Appointments: Department of Immunology Microbiology
Department of Public Health Sciences
9. Citizenship: U.S.A
10. Visa Type: N/A

II. HIGHER EDUCATION:

11. Institutional:

<i>Institution</i>	<i>Degree</i>	<i>Date</i>
Rensselaer Polytechnic Inst., N.Y.	B.S.	06/72
University of Illinois, Urbana, IL.	M.S.	1972-1974 (Physics)
University of Illinois, Urbana, IL.	Ph.D.	1974-1977 (Physics)
University of Miami Sch of Med, Miami, FL	Post-Doc Pharm.	10/77-6/80
University of Miami Sch of Med, Miami, FL	M.D.	06/81-6/83
George Washington University, Washington, DC	Residency	1983 - 1986
Exp. Immunology Branch, NCI, NIH	Medical Staff Fellow	1986 - 1988

12. Non Institutional Not Applicable

13. Certification and Licensure

<i>Description</i>	<i>Board or Agency</i>	<i>Date</i>
Internal Medicine	American Board of Internal Medicine	1986
Florida License	ME0053666	1988

III. EXPERIENCE

14. Academic:

<i>Institution</i>	<i>Rank/Status</i>	<i>Dates</i>
University of Illinois Department of Physics	Teaching Assistant	1972 - 1977
Department of Pharmacology University of Miami School of Medicine	Research Assistant Professor	1980 - 1981
Department of Medicine University of Miami School of Medicine	Assistant Professor Associate Professor	1988 -1994 1994 – 2006
Department of Immunology/Microbiology University of Miami School of Medicine	Secondary Appointment Assistant Professor Associate Professor	1989 - 1994 1994 – 2006
University of Miami School of Medicine Department of Medicine	Director of Adult HIV and Hemophilia Services	1996 - 1999
University of Miami School of Medicine Department of Epidemiology	Secondary Appointment Associate Professor	1998 – 2006
University of Miami Department of Medicine	Director of Adult HIV Services	1999 – 2010
University of Miami Department of Medicine Division of Infectious Disease	Director of Clinical Research Unit	1999 – 2012
Div. of Infectious Disease, DoM University of Miami	Associate Chief of ID	2000 – 2010
Department of Medicine University of Miami	Chief Compliance Officer	2010 – 2014
Miller School of Medicine University of Miami	Director of Medical Compliance	2012-2014
Department of Immunology/Microbiology University of Miami School of Medicine	Graduate Faculty	1993-present
Department of Medicine University of Miami School of Medicine	Professor	2006-present

Department of Immunology/Microbiology University of Miami School of Medicine	Professor (2 ^o)	2006-present
Department of Public Health Sciences University of Miami School of Medicine	Professor (2 ^o)	2006-present
Comprehensive AIDS Program University of Miami	Director	2007-present
Department of Medicine University of Miami	Clinical Director of Adult HIV Services	2010-present
University of Miami Department of Medicine, UMMSM	Vice-Chair for Clinical Affairs	2014-present
University of Miami Miller School of Medicine	LCME Faculty Accreditation Lead	2015-present
University of Miami Miller School of Medicine	Project Medical Director, UHealth Regional Alliance	2015-2018
University of Miami Miller School of Medicine	Director, Office of Academic Accreditation	2017-present
University of Miami Miller School of Medicine	Medical Director, Population Health	2018-pres

15. Hospital Appointments

<i>Institution</i>	<i>Rank</i>	<i>Dates</i>
Jackson Memorial Hospital	Attending Physician	1988-present
University of Miami Hospital & Clinics	Attending Physician	1988 – present
University of Miami Hospital	Attending Physician	2008 – present

16. Non-Academic

DMAT, DHHS	Medical Officer	2014-2017
------------	-----------------	-----------

17. Military

Not Applicable

IV. PUBLICATIONS

18. Books and monographs published:

K Goodkin, S Symes, M Concha, **M Kolber**, D Asthana, R Molina, A Frasca, W Zeng, S O'Mellan, and MdC Lichtenberger, "HIV-1 infection, diabetes mellitus, and psychiatric

disorders”, in Psychiatric Disorders and Diabetes Mellitus, Ed. MD Llorente and JE Malphurs, CRC Press, 89-114 (2007)

MA Kolber and H Terabayashi, “Cytotoxic T lymphocytes can be generated against acetaldehyde-modified syngeneic cells”, in Alcohol & Alcoholism Suppl.1, Eds. H. Kalant, J.M. Khanna, Y. Israel, Pergamon Press, 277-280 (1991)

C van Breemen, **MA Kolber** and P. Aaronson. Effects of Changing Sodium Gradient on Calcium Fluxes in Smooth Muscle.

In: The Role of Salt in Cardiovascular Hypertension. Ed. M.J. Fregly, Academic Press, 425-441 (1981)

19. Juried or refereed journal articles and exhibitions:

1. Martinez C, Rikhi R, Haque T, Fazal A, **Kolber M**, Hurwitz BE, Schneiderman N, Brown TT. Gender Identity, Hormone Therapy, and Cardiovascular Disease Risk. *Curr Probl Cardiol*. 2018 Sep 20. pii: S0146-2806(18)30142-7. doi: 10.1016/j.cpcardiol.2018.09.003.
2. **Kolber MA**, HIV Solid Organ Transplantation: Looking Beyond Hope. *AIDS*. 2018 Aug 24;32(13):1733-1736. doi: 10.1097
3. **Kolber MA**, Rueda G, Sory JB, Modelling the Impact of New Patient Visits on Risk Adjusted Access at Two Clinics. *J Eval Clin Prac*. 2018 24(3):585-589. DOI: 10.1111/jep.12938
4. Doblecki-Lewis S, Liu AY, Fester DJ, Cohen SE, Elion R, Bacon O, Coleman M, Cardenas G, **Kolber MA**. Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration Project, *J Acquir Immune Defic Syndr*. 2018 1;79(1):62-69
5. McIntosh RC, Lobo JD, Fajolu O, Reyes E, Pattany PM, **Kolber MA**. Greater N-Acetylaspartate to creatine ratio within left anterior insula predicts sympathetic imbalance in postmenopausal women living with hypertension and/or HIV. *Heart Mind* 2017;1:112-8
6. Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Chege W, Buchbinder SP, **Kolber MA**, Elion R, Shlipak M, Liu AY. Changes in Kidney Function Associated with Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. *J Acquir Immune Defic Syndr*. 2017 Oct 4.
7. Gandhi M, Murnane PM, Bacchetti, Elion R, **Kolber MA**, Cohen SE, Horng H, Louie A, Kuncze K, Koss CA, Anderson PL, Buchbinder S, Liu A. Hair Levels of PrEP Drugs Measure Adherence and are Associated with Renal Decline Among Men/Transwomen in an Open Label PrEP Study. *AIDS* 2017 Oct 23;31(16):2245-2251
8. Doblecki-Lewis, S, Liu, A, Feaster, D, Cohen, SE, Cardenas, G, Bacon, O, Andrew, E; **Kolber, MA**. Healthcare Access and PrEP Continuation in San Francisco and Miami Following the U.S. PrEP Demo Project. *J Acquir Immune Defic Syndr*. 2017 Apr 15;74(5):531-538

9. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, **Kolber MA**. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. *JAMA Intern Med*. 2016 Jan;176(1):75-84. doi: 10.1001/
10. Castel AD, Feaster DJ, Tang W, Willis S, Jordan H, Villamizar K, Kharfen M, **Kolber MA**, Rodriguez A, Metsch L. Understanding HIV Care Provider Attitudes Regarding Intentions to Prescribe PrEP. *J Acquir Immune Defic Syndr*. 2015 Dec 15;70(5):520-8. doi: 10.1097
11. Wawrzyniak AJ, Rodríguez AE, Falcon AE, Chakrabarti A, Parra A, Park J, Mercogliano K, Villamizar K, **Kolber MA**, Feaster DJ, Metsch LR. Association of Individual and Systemic Barriers to Optimal Medical Care in People Living With HIV/AIDS in Miami-Dade County. *J Acquir Immune Defic Syndr*. 2015 May 1;69 Suppl 1:S63-72.
12. Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, Matheson T, Trainor N, Blue RW, Estrada Y, Coleman ME, Elion R, Castro JG, Chege W, Philip SS, Buchbinder S, **Kolber MA**, Liu AY. High Interest in Pre-exposure Prophylaxis Among Men Who Have Sex with Men at Risk for HIV-Infection: Baseline Data from the US PrEP Demonstration Project. *J Acquir Immune Defic Syndr*. 2015 Apr 1;68(4):439-48.
13. Doblecki-Lewis S, **Kolber MA**. Preventing HIV Infection: Pre and Post-Exposure Prophylaxis, *IUBMB Life*. 2014 Jul;66(7):453-61
14. Rodriguez AE, Castel AD, Parish CL, Willis S, Feaster DJ, Kharfen M, Cardenas GA, Villamizar K, **Kolber M**, Vazquez-Rivera, Metsch LR. HIV Medical Providers' Perceptions of the Use of Antiretroviral Therapy as Nonoccupational Postexposure Prophylaxis in 2 Major Metropolitan Areas. *J Acquir Immune Defic Syndr*. 2013; 64 (suppl 1):
15. Glémaud M, Illa L, Echenique M, Bustamante-Avellaneda V, Gazabon S, Villar-Loubet O, Rodriguez A, Potter J, Messick B, Jayaweera DT, Boulanger C, **Kolber MA**. Abuse and Mental Health Concerns Among HIV-Infected Haitian Women Living in the United States. *J Assoc Nurses AIDS Care*. 2013 Sep 24.
16. Strbo N, Vaccari M, Pahwa S, **Kolber MA**, Doster MN, Fisher E, Gonzalez L, Stablein D, Franchini G, Podack ER. 2013. Novel vaccination modality provides significant protection against mucosal infection by highly pathogenic SIV. *Cutting Edge J Immunology* 2013; 190: 2495-9
17. Strbo N, Vaccari M, Pahwa S, **Kolber MA**, Fisher E, Gonzalez L, Doster MN, Hryniewicz A, Felber BK, Pavlakis GN, Franchini G, Podack ER. Gp96(SIV)Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. *Vaccine*. 2011 Mar 21;29(14):2619-2
18. Bofill L, Waldrop-Valverde D, Metsch L, Pereyra M, **Kolber MA**. Demographic and psychosocial factors associated with appointment attendance among HIV-positive outpatients. *AIDS Care*. 2011 May 11:1-7.

19. **Kolber MA**, Buendia P, DeGruttola, Moore RD. HIV-1 diversity after a class switch failure. *AIDS and Human Retroviruses* 2010;26:1176-80
20. Jaffer AK, Campo RE, Gaski G, Reyes M, Gebhard R, Ginzburg E, **Kolber MA**, Macdonald J, Falcone S, Green BA, Barreras-Pagan L, O'Neill WW. An Academic Center's Delivery of Care After the Haitian Earthquake. *Ann Intern Med.* 2010 Aug 17;153(4):262-5
21. Strbo N, Pahwa S, **Kolber MA**, Gonzalez L, Fisher E, Podack ER. Cell secreted Gp96-Ig-peptide complexes induce lamina propria and intraepithelial CD8+ cytotoxic T- lymphocytes in the intestinal mucosa. *Mucosal Immunology* 2010; 3:182-92
22. **Kolber MA**. CD38+CD8+ T-cells negatively correlate with CD4 Central Memory Cells in virally suppressed HIV-1 infected individuals. *AIDS.* 2008, 22:1937-41
23. Strbo N, de Armas L, Liu H, **Kolber MA**, Lichtenheld M and Pahwa S: IL-21 augments NK effector functions in chronically HIV-infected individuals, *AIDS* 2008, 22:1551-60
24. **Kolber MA**, Development of drug resistance mutations in patients on highly active antiretroviral therapy: Does competitive advantage drive evolution, *AIDS Reviews* 2007; 9:68-74
25. **MA Kolber**, MO Saenz, TJ Tanner, KL Arheart, H Liu, S Pahwa, Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation. *Clin Immunol* 2008;126:315-21.
26. **MA Kolber**, MO Saenz, O Gomez-Marin, LJ Tamariz, Race and ethnicity impact on the maximum proliferative response in PBL from sero-positive individuals. *HIV Med* 2007;8; 401-5
27. AE Rodriguez, LR Metsch, G Saint-Jean, E Molina, **M Kolber**. Differences in HIV-related hospitalization trends between Haitians and US-born blacks. *JAIDS* 2007: 45:529-34
28. L. White, S Krisham, N Strbo, H Liu, **MA Kolber**, MG Lichtenheld, S Pahwa. Differential effect of IL-21 and IL-15 on perforin expression, lysosomal degranulation and proliferation in CD8 cells of patients infected with Human Immunodeficiency Virus-1 (HIV). *Blood* 2007; 109:3873-8.
29. **Kolber MA**. A K103N Mutation is not an Absolute Contraindication to Adding Efavirenz to a Salvage Regimen: A Case report. *AIDS* 19:1337-38 (2005).
30. RE Campo, R. LaLanne, T.J. Tanner, D.T. Jayaweera, A.E. Rodriguez, L. Fontaine and M.A. **Kolber**. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. *AIDS* 19:447-452 (2005)
31. M. A. **Kolber**, M.O. Saenz, and S. Kaul. Memory Responses in HIV-1 Infected Individuals with Long-Term Viral Load Suppression are Independent of CD4 Cell Nadir. *Clin. Diagn. Lab. Immunol.* 12;76-80 (2005)

32. RE Campo, CE Campo, G Peter, J Zuleta, NA Wahlay, , T Cleary, MA **Kolber**, GM Dickinson. Differences in Presentation and Outcome of Invasive Pneumococcal Disease among Patients with and without HIV Infection in the Pre-HAART Era. *AIDS Patient Care and STDs*. 19:141-149 (2005)
33. M.A. **Kolber**. The Impact of Immune Plasticity on the Development of Cellular Memory Responses To HIV-1. *Clin. Diagn. Lab. Immunol.* 11;1002-7 (2004)
34. M.A. **Kolber**, RE Campo, GM Dickinson. Development of Anti-Retroviral Resistance of HIV-1 Infected Individuals on therapy: Is it inevitable? *IUBMB Life* 56; 301-7 (2004)
35. D.T. Jayaweera, M.A. **Kolber**, M. Brill, T. Tanner, R. Campo, A. Rodriguez, H-M Chu, V. Garg. Efficacy and tolerability of a once daily Amprenavir/Ritonavir containing HAART regimen in antiretroviral naïve patients at risk for non-adherence: 48 week results after 24 weeks of directly observed therapy. *HIV Med.* 5:364-370 (2004)
36. Patarca R, Isava A, Campo R, Rodriguez NJ, Nunez E, Alter M, Marchette M, Sanabia MM, Mitchell C, Rivera D, Scott G, Jayaweera D, Moreno J, Boulanger C, **Kolber** M, Mask CW, Sierra EM, Vallejo R, Page JB, Klimas NG, Fletcher M. Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: relevance of HIV-1 drug resistance testing (Part 2). *J Environ Pathol Toxicol Oncol.* 22(4):235-79 (2003)
37. Patarca R, Isava A, Campo R, Rodriguez NJ, Nunez E, Alter M, Marchette M, Sanabia MM, Mitchell C, Rivera D, Scott G, Jayaweera D, Moreno J, Boulanger C, **Kolber** M, Mask CW, Sierra EM, Vallejo R, Page JB, Klimas NG, Fletcher MA. Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: relevance of HIV-1 drug resistance testing (Part 1). *J Environ Pathol Toxicol Oncol.* 22(3):201-34 (2003)
38. Alcaide ML, D. Jayaweera , L. Espinoza, M **Kolber**. Wernicke's encephalopathy in AIDS. Apreventable cause of fatal neurological deficit. A Case Report. *International Journal of AIDS and STD* 14, 712-713 (2003)
39. MA **Kolber** and MO Saenz, APC Modulation induces a Memory Response to p24 from HIV Infected Individuals. *Clin. Diagn. Lab. Immunol.* 10; 757-63 (2003)
40. Campo RE, Lichtenberger PN, Rosa I, Suarez G, Rivera FA, Rodriguez AE, Jayaweera DT, Wahlay NA, **Kolber** MA. Differences in the frequency of resistance to antiretroviral classes among HIV-1 clinical isolates. *J Clin Micro* 41: 3376-8 (2003)
41. Campo RE, Moreno JN, Suarez G, Miller N, Rivera FA, **Kolber** MA, Holder DJ, Shivaprakash M, DeAngelis DM, Wright JL, Holmes K, Schleif WA, Emini EA, Condra JH. Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. *AIDS* 17:1933-39 (2003)
42. Campo RE, Rosa I, Lichtenberger PN, Suarez G, Rivera FA, Jayaweera DT, Rodriguez AE, Wahlay NA, **Kolber** MA. Effect of class-specific therapy interruption on persistence of HIV-1 antiretroviral resistance. *AIDS Res. Hum. Retroviruses* 19:653-6 (2003).

43. DT Jayaweera, E Scerpella, M Robinson, R Rode, R Campo, A Rodriguez, R Lalane, T Tanner, M A **Kolber**, The Safety and Efficacy of a 2-drug Regimen of Indinavir and Ritonavir (400/400mg BID) in HIV-infected Individuals from an Inner-City Minority Population. *Int J STD AIDS* 14(11):732-6 (2003)
44. TL Meinking, CM Clineschmidt, C Chen, MA **Kolber**, RW Tipping, CI Furtek, ME Villar, CA Guzzo. An Observer-Blinded Study of 1% Permethrin Crème Rinse with and without Adjunctive Combing in Patients with Head Lice. *J. Pediatrics*, 141, 665-70 (2002)
45. Alcaide ML, **Kolber** M, Jayaweera D. Would Switching the Protease Inhibitors (PI) to Tenofovir be an Option in Controlling Hypertriglyceridemia Secondary to PIs? A Case Report. *International Journal of AIDS and STD* 13, 795-796 (2002)
46. MA **Kolber**, AH Gabr, A DeLaRosa, JA Glock, D Jayaweera, N Miller, GM Dickinson. Genotypic analysis of plasma HIV-1 RNA after Influenza vaccination of patients with previously undetectable viral loads. *AIDS* 16, 537-42 (2002)
47. M.A. **Kolber** and M.O. Saenz. Enhancement of antigen driven lymphocyte proliferation secondary to gp41 induced B7 expression on adherent monocytes. *Cell. Immunol.*, 241, 35-44 (2001)
48. M.A. **Kolber**, J. Hurley, J.N. Moreno, L. Cabral. In Vitro enhancement of T-cell receptor-targeted lysis after IL-2 treatment of PBL from HIV seropositive individuals. *Clinical Immunol. Immunopath.* 86, 226-234 (1998)
49. A.S. Khan, M. Gaviria, P.E. Rollin, W.G. Hlady, T.G. Ksiazek, L.R. Armstrong, R. Greenman, E. Ravkov, M.A. **Kolber**, H. Anapol, E.D. Sfakianaki, S.T. Nichol, C.J. Peters, R.F. Khabbaz. Hantavirus pulmonary syndrome in Florida: association with the newly identified Black Creek Canal virus. *Amer. J. Med.* 100, 46-48 (1996)
50. M.A. **Kolber** and P. Hill. Vincristine potentiates cytochalasin B induced DNA fragmentation in vitro. *Cancer Chemother. Pharmacol.* 30, 286-290 (1992)
51. M.A. **Kolber**. Human cytotoxic T lymphocytes and activated peripheral blood lymphocytes enhance cytochalasin B induced DNA fragmentation of indicator bystander cells. *Cell. Immunol.* 139, 208-217 (1992)
52. M.A. **Kolber**. Enhancement of redirected target cell lysis by cytotoxic T lymphocytes in the presence of cytochalasin B. *Cell. Immunol.* 133, 84-94 (1991)
53. M.A. **Kolber**, K.O. Broschat, and B. Landa-Gonzalez. Cellular DNA fragmentation is induced by cytochalasin B. *FASEB J.* 4, 3021-3027 (1990)
54. H. Terabayashi and M.A. **Kolber**. The generation of cytotoxic T lymphocytes against acetaldehyde-modified syngeneic cells. *Alcoholism: Clin. Exp. Res.* 14, 893-899 (1990)

55. M.A. **Kolber**, R.R. Quinones, and P.A. Henkart. Target cell lysis by cytotoxic T lymphocytes redirected by antibody-coated polystyrene beads. *J. Immunol.* 143, 1461-1466 (1989)
56. E. Bonvini, K.E. DeBell, M.A. **Kolber**, T. Hoffman, R.J. Hodes and M.S. Taplits. Hydrolysis of inositol phospholipids induced by stimulation of the T cell antigen receptor complex in antigen-specific, murine T cell clones: requirement for exogenous calcium. *J. Immunol.* 143, 587-595 (1989)
57. D.S. Singer, L.J. Parent and M.A. **Kolber**. Ethanol: An enhancer of transplantation antigen expression. *Alcoholism: Clin. Exp. Res.* 13, 480-484 (1989)
58. J. Nishimura, M.A. **Kolber** and C. van Breemen. Norepinephrine and GTP- γ -S increase myofilament Ca^{2+} sensitivity in α -toxin permeabilized arterial smooth muscle. *Biochem. Biophys. Res. Comm.* 157, 677-683 (1988)
59. M.A. **Kolber**, R.M. Walls, M.L. Hinners and D.S. Singer. Evidence of increased class I MHC expression on human peripheral blood lymphocytes during acute ethanol intoxication. *Alcoholism: Clin. Exp. Res.* 12, 820-823 (1988)
60. M.A. **Kolber**, R. Quinones, R. Gress and P.A. Henkart. Measurement of cytotoxicity by target cell release and retention of the fluorescent dye biscalboxyethyl carboxyfluorescein (BCECF). *J. Immunol. Meth.* 108, 255-264 (1988)
61. M.A. **Kolber** and P.A. Henkart. Quantitation of secretion by rat basophilic leukemia cells by measurements of quinacrine uptake. *Biochim. Biophys. Acta* 939, 459-466 (1988)
62. M.A. **Kolber**. Mono – and divalent competitive adsorption to a charged membrane in a closed system: A comparative study. *J Theor. Biol.* 94, 633-649 (1982)
63. M.A. **Kolber** and D.H. Haynes. Fluorescent study of the divalent cation transport mechanism of A23187 in phospholipid membranes. *Biophys. J.* 36, 369-391 (1981)
64. M.A. **Kolber** and C. van Breemen. Competitive membrane absorption of Na^+ , K^+ , and Ca^{++} ions in smooth muscle. *J. Memb. Biol.* 58, 115-121 (1981)
65. P. Aaronson, C. van Breemen, R. Loutzenhiser and M.A. **Kolber**. A new method for measuring the kinetics of transmembrane calcium-45 efflux in the smooth muscle of the guinea pig *Taenia Coli*. *Life Sci.* 25, 1781-1790 (1979)
66. D.H. Haynes, M.A. **Kolber** and S.J. Morris. Short and long range forces involved in cation induced aggregation of chromaffin granule membranes. *J. Theory Biol.* 81, 713-743 (1979)
67. M.A. **Kolber** and D.H. Haynes. Evidence for a possible role of phosphatidyl ethanolamine as a modular of membrane contact. *J. Memb. Biol.* 48, 95-114 (1979)
68. M.A. **Kolber** and J.D. Dow. Theory of two-photon electroabsorption by excitons. *Phys. Rev. SB18*, 5499-5501 (1978)

69. M.A. **Kolber** and J.D. Dow. Exchange mixing of L_{II, III} X-ray edges. J. Phys. Soc. Jap. 45, 855-859 (1978)
70. M.A. **Kolber** and R.K. MacCrone. Bound polaron hopping in NiO. Phy. Rev. Lett. 29, 1457-1461 (1972)

Clinical Trial Groups Reviewed Publications:

1. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. INSIGHT START Study Group, Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807
2. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3):e1001809.
3. Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med. 2015 Apr;16 Suppl 1:1-9.
4. Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014 May 28;3(3)
5. Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee. Factors associated with D-dimer levels in HIV-infected individuals. PLoS One. 2014 Mar 13;9(3):e90978
6. Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group. Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). HIV Med. 2011 Apr;12(4):219-27.
7. INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009 Oct 15;361(16):1548-59.

20. Other works and publications:

Cohen SE, Vittinghoff E, Doblecki-Lewis S, Coleman M, Bacon O, Elion R, **Kolber MA**, Buchbinder S, Liu AY. Authors' Reply: Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States. J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):e33-5.

Ph.D. Thesis:

Studies of the Optical Properties of Solids:

- I. Two Photon Electroabsorption
- II. Electron Hole Exchange Coupling at L_{II, III} X-ray Edges

21. Other works accepted for publication:

Kolber, MA. Invited Book review: Cytokines and Chemokines in Infectious Diseases, Clinical Infectious Disease 2003; 37:1146

V. PROFESSIONAL

22. Funded research performed (last 6yrs):

2011-2012	5P30AI087714-02 The District of Columbia Developmental Center for AIDS Research (DCD-CFAR) Supplement Title: Enhanced Comprehensive HIV Prevention Planning Initiative (CFAR ECHPP Initiative) site PI: Metsch (Kolber investigator-5%)
2007-2012	P30 AI073961 (Pahwa) 6/1/07-5/31/12 NIH :University of Miami Developmental Center for AIDS Research (DCFAR) Kolber: Behavioral Core Faculty (2%)
2009-2013	FL Department of Health (Kolber:Director) Grandmothers Project: A POL Project in AA Churches in S Dade Direct: \$165,000.00/yr
2012-2014	1U01AI069451: NIAID PrEP DEMONSTRATION PROJECT (Yr 1&2 \$1,896,068 (\$1,239,260 direct) University of Miami Pediatric/Perinatal HIV/AIDS Clinical Trial Network Miami Pre-exposure Prophylaxis Project (Project Director: Kolber 20%-funds restricted to Dr. Kolber)
2012-2017	2P30AI073961-06-6205 Miami CFAR (PI: S. Pahwa) Behavioral/Social Sciences & Community Outreach Core Total Cost FY12 \$373,057 Core E co-director: Kolber (5%)
2014-2015	2UM1AI069496: NIAID

PrEP DEMONSTRATION PROJECT

(Yr 3 \$1,054,892 (\$687,226 direct)

San Francisco Clinical Trial Network –Dr. Buchbinder

Miami Pre-exposure Prophylaxis Project

(Project Director: Kolber 25%-funds restricted to Dr. Kolber)

1/2015-12/2017

H76HA00095 (J Potter, PI, Kolber co-PI [15%])

Ryan White Part C Outpatient EIS Program (recompete)

Total: \$942,667 annual

2011-2017

START-Strategic Timing of Antiretroviral Treatment

NIH

Clinical Trial Site

Site Leader: Kolber

2014-2018

H97HA27433 (Rodríguez, A., PI, Kolber Co-PI [5%])

HRSA SPNS: System-level Workforce Capacity Building for Integrating HIV Primary Care in Community Health Care Settings - Demonstration Sites.

Total \$300k/yr

CURRENT:

2017-2022

NIDA 1 RO1 DA045713

(PI: Daniel J. Feaster, Lisa R. Metsch & Julie Burneau)

A MULTI-SITE MULTI-SETTING RCT OF INTEGRATED HIV PREVENTION AND HCV CARE FOR PWID

Total: \$8,8180,899

Kolber 5% Investigator

2017-2022

2P30AI073961-06-6205

Miami CFAR (PI: S. Pahwa)

Behavioral/Social Sciences & Community Outreach Core

Total Cost FY12 \$373,057

Core E co-director: Kolber (5%)

CLINICAL GRANTS/CONTRACTS

2013-2019

Dade County Competitive Part A Contract annual direct \$1,934,380/yr
(Kolber PI; 15%)

7/2015-6/2019

SE AETC (Vanderbilt) for Miami Site \$984,555 Total (Kolber S FL site
PI; 25%)

1/2017-12/2018

H76HA00095 (J Potter, PI, Kolber co-PI [15%])

Ryan White Part C Outpatient EIS Program (recompete)

Total: \$942,667 annual

23. Editorial responsibilities: none

24. Professional and Honorary Organizations:

1987-present	Member of the American College of Physicians
1990-present	Member of the American Association of Immunologists
1995-2015	Member of the Clinical Immunology Society
2000-present	Member Infectious Diseases Society of America/HIVMA

25. Honors and Awards:

1977-1979	Institutional National Research Service Award in Cardiovascular Pharmacology, University of Miami
1979-1980	Individual National Research Service Award in Department of Pharmacology, University of Miami
1994 -1997	Cross-Step Task Force for Immunity, USMLE
Sept 18, 2009	The Flowers Heritage Foundation Award for Innovative Leadership in Public Health
Jan 9, 2012	11 th Annual CAEAR Coalition Partnership Awards: Award recipient-The CAEAR Coalition Partnership Awards were established to acknowledge individuals and organizations that have made profound contributions in the fight against HIV/AIDS and who have worked in partnership with the Coalition in making the Ryan White community-based systems of care exemplary models for effective disease management.
February, 2012	UMMG Faculty Heroes Recognition Award
Dec 12, 2012	White House Forum on National HIV/AIDS Strategy, panelist-Miami, FL
March, 2013	Alpha Omega Alpha
June 18, 2014	White House Meeting on HIV in the Southern United States: panelist-DC
July 3, 2015	White House Meeting Panelist: National HIV/AIDS Strategy –Atlanta, GA
Feb 20, 2016	Distinguished Service Award, Health Rights Clinic 10 th Yr Anniversary, Univ. Miami Law School
Sept –Dec 30, 2016	“Getting to zero” Mayors Task Force, Miami-Dade County

26. Post Doctoral Training:

1977-1980	University of Miami School of Medicine Department of Pharmacology
-----------	--

1983-1986	Miami, Florida George Washington Hospital Medicine, Internship & Residency Washington, D.C.
1986-1988	National Cancer Institute Experimental Immunology Branch, National Institutes of Health, Fellowship Bethesda, MD.

27. Other Professional Activities:

Scientific presentations at national & international meetings:

August 22, 2002	Invited by Dr. J. Tavel, NIAID, NIH to speak on “Functional Immune Reconstitution in HIV Disease”
June 19, 1990	Invited speaker at the symposium Acetaldehyde-Protein Adducts: Immunologic and Metabolic Aspects at the 5th Congress of The International Society for Biomedical Research on Alcoholism/Research Society on Alcoholism
April 22, 1991	Invited minisymposium speaker at FASEB on Programmed Cell Death
March, 1996	Invited by Dr. R. Walker, NIAID, NIH to speak on “Recovery of $\alpha\beta$ -heterodimer targeted lysis from peripheral blood lymphocytes of HIV-seropositive individuals after Interleukin-2 treatment”
June, 1997	Invited speaker at Symposium on Streptococcal and scabies in Darwin, Australia-“Immunopathogenesis of crusted scabies in HIV and non-HIV infected people”
Sept 24-25, 2009	Group facilitator, Interdisciplinary Collaborative Education Conference, Atlanta, GA
May 4-8, 2010	Conference on Clinical Legal Education, Baltimore MD: panel/speaker-What Legal Clinicians (Still) Have to learn from the Medical Clinical Model: Legal and Social Justice Lessons from the Trenches
May 25, 2010	5 th International Conf. on HIV Treatment Adherence; Engaging Patients in HIV Care: Challenges and Successes in Miami-Dade County
April 30, 2014	Invited speaker at the DoH "Test Miami Member Appreciation Day", Title of talk "Treatment as Prevention:PrEP and nPEP"

VI. TEACHING:

28. Teaching awards received:

5/25/2007	Chief Medical Residents recognition for teaching and commitment to the Internal Medicine Residency Program and its residents
-----------	--

6/06/2018

Barkin/Rogers Outstanding Mentor Award, DOM

29. Teaching Specialization:

1988-2005	Annual lectures in Department of Immunology and Microbiology
1989, 1996	Medical Grand Rounds
1997	Module Coordinator and Lecturer in graduate course, "Research Opportunities in Human Disease", in Molecular and Cellular Pharmacology
1/1999	Endocrine Grand Rounds
1998	Grand Rounds in the Clinical Immunology Section
1999	Medical Grand Rounds, Mercy Hospital
2000-2004	Annual lectures in the Clinical Immunology Grand Rounds
2001	Immunology of HIV, HIV Nursing Management Conference
2002	"Medical Compliance for the Physician", University of Miami School of Medicine-Department of Medicine Division of Hematology/Oncology
8/2002	Grand Rounds on "Immune Reconstitution in HIV Disease". University of Miami School of Medicine-Department of Dermatology
6/2002	"Medical Compliance for the Physician", University of Miami School of Medicine- Department of Medicine
6/2002	"Medical Compliance for the Physician" University of Miami School of Medicine Department of Medicine- Division of Hepatology
6/2002	"Medical Compliance for the Physician" University of Miami School of Medicine Department of Medicine- Division of General Medicine
5/2002	"Medical Compliance for the Physician". Speaker for the Department of Medicine – Division of Infectious Diseases University of Miami School of Medicine
2002	"HIV Care Today and Tomorrow" Managed Care Seminar Jackson Memorial Hospital
2002	HIV Disease Management JMH Case Management conference
2002	HIV Disease Management Update Williams, Stern & Ass.
2003-2006	Annual HIV/AIDS: Overview-2 nd year medical students
2003	Grand Rounds on Immune Reconstitution in HIV Disease University of Miami School of Medicine Department of Medicine
2003	HIV Care: Disease Management Update AETC/ Positive Healthcare

2003	Immunology Fellows Lecture Series: HIV Immunology
2003	Grand Rounds: Update: HIV/AIDS University of Miami School of Medicine Department of Plastic Surgery
2003	Faculty Research Seminar University of Miami School of Medicine Department of Medicine
2004	HIV Winter Symposium: Evidence for long-lived memory responses in HIV-1 infected individuals with long term viral load suppression
2004	Infectious Disease/HIV Grand rounds: Current Thinking about the immunology of HIV
2004	Microbiology /Immunology Lecture: Innate Immunity and HIV: Friend or Foe?
2005	Teaching Resident lecture series on HIV/AIDS
2005	GI & Renal: Billing and Compliance Seminar
2006	Lecturer in Micro/Immunology: MIC 628: Advanced Cellular and Molecular Immunology
2007	HIV Grand Rounds-Emerging Therapies in HIV
2008	Grand Rounds “Emerging HIV Therapies: New Targets: New Technologies”University of Miami Miller School of Medicine Department of Medicine
2009	Infectious Disease fellows conference: Billing/Compliance
2009	Grand Rounds: HIV Update University of Miami Miller School of Medicine Division of General Medicine
2010	DCFAR Grand Rounds: Is Early Treatment of HIV Infected Individuals the Correct Course: Arguments For and Against
2010	Infectious Disease fellows conference: Billing/Compliance
2011	Separate Documentation & Compliance Talks in Pulmonary, General Medicine, ID, Hepatology, Renal, Rheumatology, Endocrinology, Hospital Medicine, Oncology
2012	Separate Documetation & Compliance Talks in Cardiology, Neurosurgery, Pediatrics

30. Thesis and dissertation advising:

1988-1990	Hiditaka Terabayshi, MD, Hepatology Fellow, Research
1994-1995	Ge Deng, Member Ph.D. Thesis Committee, Depart. Micro/Im
1994-1995	Albert Mestre, M.D., ID fellow, Research on MAIDS
2006	Lina Bofill, MPH Thesis Committee. Depart of Public Health
2014	Louis Gonzalez PhD, PhD Thesis Committee, Depart. Micro/Imm
2014-2015	Diane Byrnes MPH, CAPSTONE Project (MD/MPH Program)
2013-2016	Ryan McCormick, PhD Thesis Committee, Depart. Micro/Imm

VII. SERVICE:

31. Committee and Administrative Responsibilities:

1990-1993	Member, Executive Promotions Committee
1990-1993	Organizer of the Faculty of Medicine seminar series
1990-1993	Member, Internship Selection Committee
1991-1994	Member, Scientific Advisory Committee
1992-1994	Member, Medical School Admissions Committee, Ph.D.-M.D.
1994-1997	Member, Professional Standards and Practice Committee
1994-1995	Member, Department of Med. Committee on P&T Guidelines
1997-2003	Member, Clinical Research Advisory Committee, Department of Medicine
1997-2003	Member, Resident Scientific Advisory Committee, Department of Medicine
1997-2003	Founder and Director, Corporate Partners Program for HIV Education and Research
1998-2007	Oversight Committee member, Comprehensive AIDS Program
2000-2004	University Institutional Priorities Committee, Member
2000-2004	Member, HIV search Group Committee, Immunology/Microbiology
2001-2002	Member, Selection Committee for new GI Chief, Department of Medicine
2004	Member: JMH Capital Asset Committee
2004-2005	Member: AIDS Capitation Working Group: JMH & AIDS Healthcare Foundation
2004-2005	Clinical Research Building Steering Committee
2006-2007	Director of Research for ID fellows
2006-2007	Member, Research Advisory Committee, Department of Medicine
2008-2012	Member, Promotion and Tenure Committee, Department of Medicine
2008-2010	Member, Peer Review Committee, Department of Medicine
2011-2015	UMMG Leadership Council, member
2012-2015	University Conflict of Interest Committee, member
2012-Pres	Faculty Assistance Committee, UM School of Medicine-member
2013-2015	Steering Committee on ICD10 Implementation
2014-2016	Jackson/UMH revenue cycle committee, UMMSM
2016-Pres	Jackson/UM monthly Clinical Operational Leadership meeting
2017-Pres	Learner Mistreatment Taskforce Working Group

32. Community Activities:

1998-1999	Technical Advisory Committee, Health Council of South FL., Inc.
1998- 1999	Executive Committee for Hemophilia of GA, Inc.
1998	Community Liaison Group (Dr. Karl Goodkin in Psychiatry), Seminar: "University and Community Partnership in Clinical and Research"

1998-2003	Member, Steering Committee of the HIV Managed Care Network, IDSA
1999	Member of the Medical Care Subcommittee for the Miami-Dade Partnership in HIV/AIDS
2000	Invited speaker at the Miami Fellows Initiative
2001-2005	Community Advisory Board, CDC INSPIRE- Dr. Metsch
2001	Member, advisory group for Kaiser Family Foundation and the Forum for Collaborative HIV Research (FCHR) to survey HIV Physicians on their adoption of the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, D.C.
2002	Invited consultant at meeting on Impact of Caribbean Migration of HIV Individuals sponsored by HRSA/HIV/AIDS Bureau, and PAHO, Washington, DC
2004	Fighting Medicaid Cuts: Strategic Planning and Advocacy-invited participant
2005	Invited speaker 14 th Annual HIV Conference, FL. AETC-“Future therapeutics”
2007	Invited speaker 16 th Annual HIV Conference, FL. AETC-Orlando “Emerging Therapies”,
2008	Invited speaker 17 th Annual HIV Conference, AETC: Orlando “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents: The Reasons Behind Them”
2008-2013	Member, Health Impact Counsel for United Way
2008-2009	Graduate, Leadership Miami Program, Miami Chamber of Commerce
2009	HIV Update, Carnival Cruise Line HealthCare Symposium,
2009	HIV Update, Grand Rounds Palmetto General Hospital
2009-2011	Physician Ambassador DOH Test Miami campaign
2010	UM Medishare Haiti Earthquake Relief, CMO, Haiti
2010	Member, Clinical Information Systems Physicians Working Group, JMH
2011	North Shore Hospital, Grand Rounds on HIV Update, Miami, FL
2011	Jackson North Hospital, Grand Rounds on HIV Update, Miami, FL
2011	FL-DOH, PrEP Talk, (Oct) Broward, FL
2013	PrEP Demo Project Talk, FL-DOH (Dec 13), Miami, FL
2014	FL-DOH AIDS Day Speaker (Dec 1), Miami, FL
2015	FL PrEP/nPEP Stakeholder’s Meeting Consultant, Orlando FL
2015	World AIDS Day, Chamber of Commerce Trustees Lunch, speaker Dec 1, Miami, FL
2016	AIDS-FREE:A Community Dialogue to Design the end of AIDS in Florida- Feb 4, 2016
2016-2017	Getting to Zero –Care and Treatment Taskforce-2017
2018	Community RW Part A HIV Test and Treat Expansion Meeting

